Which drug stops TBI seizures best? new study aims to find out

NCT ID NCT06866691

Recruiting now Disease control Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two common seizure medications, levetiracetam and lacosamide, to see which works better at preventing early seizures after a traumatic brain injury. Researchers will also track side effects like agitation and sedation. The trial plans to enroll 600 adults with moderate to severe brain injuries.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: levetiracetam (Keppra) and lacosamide (Vimpat)
What this could lead to: If successful, this could show which drug better prevents early seizures after a traumatic brain injury with fewer behavioral side effects, helping guide standard care.
What could go wrong: This is a phase 4 study comparing two already-approved drugs, so no new treatment is being discovered. Results may not apply to all brain injury patients, and individual responses vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRAUMATIC BRAIN INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Brain Injuries, Traumatic brain injury traumatic brain injury post-traumatic epilepsy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRAUMATIC BRAIN INJURY

Contacts and locations

Locations

Wake Forest University Health Sciences
RECRUITING

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.